LogicMark Inc (LGMK) Fair Value & Analysis
Healthcare · US · Market cap $675K · ISIN US67091J5039
LogicMark Inc
LGMK · US
Risks
Fair value as of: Aug 28, 2026
From 3 valuation models · updated 3 days ago
Share price +92.3% over the past month.
Below-average quality, and trading another 99% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.9510). The favourable scenario is already priced in.
- Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide ($0.3156 to $0.9510). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range $0.4300 – $1,000,000 · fair‑value band $0.3156 – $0.9510 · the $1.25 price screens above the $0.6290 fair value. Dashed = 300-day average. As of Aug 28, 2026.
Analysis
LogicMark Inc (LGMK) currently trades at $1.25, while our model-based Fair Value estimate is $0.6290, implying the stock looks roughly 49.7% overvalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, LogicMark Inc generated revenue of $12.0M at a net margin of -55.8%. Revenue grew 24.0% year over year. It earns a return on equity of -33.9%. The balance sheet holds a net cash position of $3.8M. Fundamentals as of Aug 28, 2026
Our scenario range runs from $0.3156 (bear case) to $0.9510 (bull case); at $1.25, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 77% below its 52-week high and 257% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -68% fair-value upside, at -50%, LGMK screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 52.43 USD per share, which is 8,336.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based ($13.47) versus Dividend Discount ($3.69). Highest evidence: Gordon GGM (68).
Notify me when LGMK reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 34 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company offers Guardian Alert 911 Plus, Freedom Alert, Freedom Alert Mini, and Freedom Alert Max, which are home-based landline solutions.
Full company description
LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company offers Guardian Alert 911 Plus, Freedom Alert, Freedom Alert Mini, and Freedom Alert Max, which are home-based landline solutions. It also provides Aster, a personal safety app that provides 24/7 monitoring along with a Bluetooth button product. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was incorporated in 2012 and is based in Louisville, Kentucky.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
LogicMark Inc reported revenue of $11.4M in FY2025 versus $10.0M in FY2021, a compound +3.3%/yr. Reported net income was −$7.5M in FY2025.
LGMK screens 99% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 131 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $282.13 | $91.49 | -68% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | -69% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| Privia Health Group PRVA | $21.07 | $5.26 | -75% |
Compare LogicMark Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is LogicMark Inc (LGMK) overvalued or undervalued?
What is the fair value of LGMK?
What is the quality score of LGMK?
What is the revenue of LogicMark Inc (LGMK)?
What is the net profit margin of LGMK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch LogicMark Inc in the live analysis
One click puts LogicMark Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.